Perhaps we can liquidate our 'new' shares at a loss to cover the taxes. Seems
the stock should drop after the sale.
Nice that the execs took care of the taxes for themselves. It's not going to be a
very pretty next shareholders meeting.
-John
On Jun 19, 2014, at 6:18 PM, "BKremser"
<bkremser@comcast.net<mailto:bkremser@comcast.net>> wrote:
This Article from StarTribune.com<http://www.startribune.com> has been sent to you
by BKremser.
*Please note, the sender's identity has not been verified.
The full Article, with any associated images and links can be viewed
here<http://www.startribune.com/business/263747631.html>.
Schafer: Medtronic deal gives investors a big tax hit
LEE SCHAFER, Star Tribune
Medtronic’s executives haven’t mentioned that its $42.9 billion merger and relocation to
Ireland to save on corporate taxes is actually going to generate a ton of other taxes
here.
Why not say so? Perhaps because the company’s not paying them. Its shareholders will be.
The tax bite coming for longtime Medtronic shareholders is just one more curious aspect of
the Fridley-based company’s combination with Covidien and establishment of its formal
headquarters in Dublin.
Holders of the stock may not yet have figured it out, because didn’t the news release
Sunday say “acquire” in the headline?
Any seasoned investor knows that when a company in which he owns stock buys another, it’s
not taxable. No shares are being sold. No gain to be calculated. No taxes.
Not this time. When holders exchange their Medtronic stock for shares in an Ireland-based
company the regulatory filings refer to as “New Medtronic,” it’s treated like a sale — a
sale that will generate a tax but no cash proceeds that could be used to pay it.
Medtronic hasn’t hidden this information, exactly, but all Chief Financial Officer Gary
Ellis said on the Monday morning investor conference call was “it should also be noted”
that the transaction will be a taxable event for federal income tax purposes for both
Medtronic and Covidien shareholders.
OK. Duly noted.
If institutional investors cared more about these kinds of taxes, maybe Medtronic would,
but they really don’t. The shareholder of a mutual fund with a lot of Medtronic stock may
not even realize, when she gets her 1099 tax notice from the fund company, that her tax
bill seems kind of big.
Individuals who own the stock in a taxable account, on the other hand, will feel it. They
will feel it like they would a kidney stone.
We are talking about long-term gains here, not selling at a profit after holding a stock
less than a year. Long term means stock held not by traders but by investors, people who
don’t trade in part to keep taxes down.
Any gain from stock held long-term is taxed at a favorable federal rate of either 15 or 20
percent for most tax filers.
Andy Beuning, corporate tax director in the Twin Cities at the accounting firm Wipfli LLP,
explained that a transaction taxable under federal law is typically taxable under state
law. With the 3.8 percent federal net investment income tax on high earners to help fund
the Affordable Care Act on top of state taxes, a Minnesotan could face up to a combined 30
percent tax rate on a 2014 sale.
The people who will pay the most are the people who owned the stock the longest, the very
people who held on because they understood that Medtronic was one of America’s great
companies.
We know it today as a pillar of the Fortune 500, a company with $17 billion in revenue and
about 49,000 employees, including more than 8,000 in Minnesota. But it’s come a long way
in 20 years.
Back then it employed just 8,700 people full-time worldwide, and revenue came to not quite
$1.4 billion. Holders who saw the opportunity could have bought stock at a split-adjusted
cost of less than $5 per share
With shares currently trading at just under $64 each, and if the deal closed at that
price, a thousand-share holder at the highest tax bracket faces tax bills of more than
$17,000.
The real old-timers who have held Medtronic stock for 30 years could have bought it at
less than 50 cents per share, adjusted for splits. The taxable long-term gain for those
folks will be all but equal to the price of the stock.
A handful of shareholders called and e-mailed this week, puzzled that the Star Tribune
would describe an acquisition as taxable to them. Several then wanted to know whether
Medtronic’s executives had really thought it through.
Of course they did. A company spokesman said that management was “fully aware of the
impact” and that by mentioning it now the company is “hopeful … that they have time to
adequately think through and prepare how they might handle it.”
Another sign of how well Medtronic’s executives understood this deal is how they handled
their own little tax problem.
Transactions like this one generate an excise tax at the capital-gains tax rate, call it
20 percent, on the value of stock compensation held by the directors and officers of the
company. The reasoning here is that it should be painful to approve a so-called inversion
transaction, when a U.S. company ends up abroad to save money in taxes.
It would’ve been painful too — had Medtronic not agreed to cover any liability for its
insiders related to this excise tax.
The company, through a spokesman, explained that the board wanted to eliminate the
potential that the insiders wouldn’t support a transaction that was clearly going to
benefit the shareholders long-term.
Of course, if the insiders were true believers, they could have taken a deep breath and
paid the tax.
But with the big tax bite coming, longtime individual holders still are trying to sort
through just how much of a benefit this deal will be.
The St. Paul investment adviser Mairs and Power manages accounts for individual clients
alongside its funds, and some clients bought Medtronic stock decades ago.
In a conversation with portfolio manager Mark Henneman, he explained that one reason he
and his colleagues have been reluctant to sell their clients’ Medtronic stock is that they
didn’t want to stick them with a tax liability. Now they will have one anyway.
“It definitely disadvantages longtime shareholders who have been extraordinarily patient
with this stock and this company,” he said of the Covidien merger. “I don’t get the sense
that their interest got considered” in the transaction.
Henneman only then learned that the company will indemnify its insiders for the related
excise tax.
“That’s interesting,” he said after a brief pause. He forgave me for breaking this news to
him, saying “I was going to hear about it from someone.”
Then he had to go. Perhaps he had some Medtronic stock to sell.
lee.schafer@startribune.com<mailto:lee.schafer@startribune.com> • 612-673-4302
_______________________________________________
jig mailing list
jig@thebarn.com<mailto:jig@thebarn.com>
http://www.thebarn.com/mailman/listinfo/jig
[CONFIDENTIALITY AND PRIVACY NOTICE]
Information transmitted by this email is proprietary to Medtronic and is intended for use
only by the individual or entity to which it is addressed, and may contain information
that is private, privileged, confidential or exempt from disclosure under applicable law.
If you are not the intended recipient or it appears that this mail has been forwarded to
you without proper authority, you are notified that any use or dissemination of this
information in any manner is strictly prohibited. In such cases, please delete this mail
from your records.
To view this notice in other languages you can either select the following link or
manually copy and paste the link into the address bar of a web browser:
http://emaildisclaimer.medtronic.com